Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Go back to Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference| Beam Inc. (NASDAQ: BEAM) | Delayed: 33.20 -2.33 (6.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.53 | 52 Week High | $83.60 | |||
| Open | $35.26 | 52 Week Low | $82.96 | |||
| Day High | $36.67 | P/E | 14.82 | |||
| Day Low | $32.79 | EPS | $2.24 | |||
| Volume | 3,604,172 | |||||
